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Abstract
Objectives To identify predictive variables of treatment re-
sponse following aspiration sclerotherapy of large symptom-
atic hepatic cysts.
Methods We collected individual patient data from two
tertiary referral centres and included all patients treated
with aspiration sclerotherapy of a large (>5 cm), symp-
tomatic hepatic cyst. At six months, clinical response
was defined as complete or incomplete. Secondary, sub-
optimal technical response was defined as lower quartile
of cyst reduction. Predictive variables of clinical and
technical response were analyzed by logistic regression
analysis.
Results We included 86 patients (58±10 years; female 90%).
Complete clinical response rate was 55 %. Median cyst
diameter and volume reduction were 71% (IQR 50-87%) and
98 % (IRQ 88-100 %), respectively. Patients with complete
clinical response had a significantly higher cyst reduction
compared to incomplete responders (OR 1.02, 95 % CI
1.00-1.04). Aspiration of haemorrhagic cyst fluid (OR 4.39,
95 % CI 1.34-14.39) or a lower cyst reduction at one month
(OR 1.06, 95 % CI 1.02-1.10) was associated with a subopti-
mal technical response at six months.
Conclusion Complete clinical response is associated with ef-
fective cyst reduction. Aspiration of haemorrhagic cyst fluid
or a restricted diameter reduction at one month predicts a
suboptimal technical treatment response, however, these var-
iables did not predict symptom disappearance.
Key Points
• Aspiration sclerotherapy of hepatic cysts shows excellent
clinical and technical efficacy.
• Optimal clinical responders have a markedly higher cyst
reduction.
• Haemorrhagic aspirate and a strong fluid reaccumulation
predict suboptimal cyst reduction.
Keywords Hepatic cyst . Polycystic liver disease .
Interventional . Drainage . Sclerotherapy
Abbreviations
CT Computed tomography
MRI Magnetic resonance imaging
PLD Polycystic liver disease
US Ultrasound
Introduction
Hepatic cysts are fluid-filled cavities that arise from congenital
malformations of biliary ducts [1]. The estimated prevalence
of these benign, non-parasitic lesions is 2-18 % in the general
population [2–4]. Hepatic cysts occur solitary or as multiple
lesions in the context of polycystic liver disease (PLD) [5].
Aspiration sclerotherapy is a minimally invasive treatment
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option and serves as first-choice treatment for symptomatic
hepatic cysts [6–8]. Aspiration sclerotherapy combines percu-
taneous drainage of cyst fluid with subsequent instillation of a
sclerosing agent that destroys the inner cyst lining. This treat-
ment is effective and safe [9–14]. There are two components
that are important to the perceived success of aspiration
sclerotherapy treatment. First, clinical response as experi-
enced by the patient, and second, technical response in terms
of reduction of the treated cyst. It is not well understood which
factors determine clinical success or are important for techni-
cal response. Due to the infrequency of large symptomatic
hepatic cysts, published studies are relatively small, which is
an obstacle on the road to identification of predictive factors.
In this study, we collected individual patient data from two
observational cohort studies with comparable treatment pro-
tocols and follow-up measurements. The goal of this study
was to identify variables that predict response of aspiration
sclerotherapy of large symptomatic hepatic cysts.
Materials and methods
Patients and study design
We performed a pooled analysis of data collected from pa-
tients that consecutively underwent aspiration sclerotherapy
in two tertiary referral centres: Radboud University Medical
Center, Nijmegen, the Netherlands (centre 1) and University
Hospitals Paris Nord Val de Seine, Beaujon, Clichy, France
(centre 2) (Table 1). Centre 1 prospectively included patients
treated within a timeframe of June 2012 toMarch 2014, centre
2 retrospectively included patients treated from December
2003 to September 2011. Within this timeframe the treatment
protocol remained unchanged. For this analysis we included a
cohort (centre 2) that was previously published to report effi-
cacy of aspiration sclerotherapy [13]. In the current study, we
extended our data by pooling this sample with a second pro-
spective cohort (centre 1). By this, we created a large sample
size that was needed to evaluate predictors of treatment
response.
Included patients were aged over 18 years and underwent
aspiration sclerotherapy of a simple, symptomatic, solitary or
dominant hepatic cyst larger than 5 cm (Fig. 1). A simple cyst
was diagnosed by ultrasound (US), computed tomography
(CT), or magnetic resonance imaging (MRI) based on the
following criteria: a well-circumscribed anechoic lesion with
increased posterior echo enhancement and no evidence of
mural nodularity on US; a water-density (−10 to 10 HU) le-
sion with sharply defined margins and smooth thin walls with
no contrast enhancement or septations on CT; or a homoge-
neous lesion, hypointense on T1-weighted images and hyper-
intense on T2-weighted images without contrast enhancement
or septations on MRI [15, 16]. A history of a previous cyst
haemorrhage was not considered an exclusion criterion. The
diagnosis of a haemorrhagic cyst was based on pre-defined
criteria [16]. If deemed necessary, serology and/or more ex-
tensive imaging was applied to rule out hydatid or (pre-)ma-
lignant lesions. Parasitic or neoplastic cysts were not treated
by aspiration sclerotherapy. In PLD patients (>20 cysts), the
largest cyst was regarded as dominant cyst. A patient was
excluded from analysis if the treated cyst could not be identi-
fied following treatment or was lost to follow-up. If a patient
underwent two or more aspiration sclerotherapy procedures of
the same cyst, only the first procedure was included in this
analysis. The institutional review board of both participating
centres approved this study and requirement for informed con-
sent was waived.
Aspiration sclerotherapy
Patients were informed about possible related risks and agreed
to undergo aspiration sclerotherapy. In both centres, patients
underwent aspiration sclerotherapy of a single hepatic cyst
following a standardized single-session percutaneous ethanol
sclerotherapy protocol [13]. The intervention was performed
with local anaesthesia and conscious sedation in centre 1, and
under general anaesthesia in centre 2. The cyst was localized
by US and punctured with a 5-French pigtail catheter (centre
1: Cook Medical, Bloomington, United States of America;
centre 2: Cordis Corporation, Bridgewater, United States of
Table 1 Design characteristics of
included studies Centre 1 Centre 2
Number of patients 29 57
Design Prospective cohort Retrospective cohort
Type treatment Single session, ethanol Single session, ethanol
Population Solitary cysts and PLD Solitary cysts and PLD
Inclusion criteria >18 y; simple, non-parasitic cyst >18 y; simple, non-parasitic cyst
Endpoints Clinical and technical outcome, safety Clinical and technical outcome, safety
Timepoints Baseline, one, and six months Baseline, one, six, and 12 months
Abbreviations: PLD, polycystic liver disease; y: years
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America) to perform complete fluid drainage of the hepatic
cyst (Fig. 2). Aspirated fluid was classified as clear or
haemorrhagic (red or brown) fluid and evaluated by micros-
copy. Subsequently, we performed fluoroscopy following in-
stillation of contrast fluid (centre 1: Iomeron 300, Bracco
Imaging, Konstanz, Germany; centre 2: Iobitridol, xenetix
350, Guerbet, France) to rule out leakage or communication
with vasculature or the biliary tree (Fig. 2). Sclerotherapy was
performed by injecting 96-100 % ethanol (centre 1: up to
50 mL, 10 minutes; centre 2: up to 150 mL, 60 minutes) in
the cyst. Following sclerotherapy, all ethanol was re-aspirated
and the catheter was removed from the patient. Patients were
discharged one day following the procedure.
Baseline and follow-up study visits
At baseline and at one and six months following aspira-
tion sclerotherapy, the patient visited the outpatient clinic
to evaluate clinical and technical parameters. In both cen-
tres, overall clinical response was assessed at six months by
standardized instruments and defined as Bdisappearance^,
Breduction^, Bno change^, or Baggravation^ of symptoms
[13, 17]. If a patient had not completed the questionnaire,
we retrospectively reviewed the patients’ clinical chart
(n=10). Detailed information of symptom assessment can
be found in the supplemental material.
The maximal cyst diameter of the treated cyst was
measured during all visits (Fig. 3). Subsequently, we
estimated cyst volume by multiplying available orthog-
onal diameters by 0.523 using the ellipsoid volume for-
mula (d1*d2*d3*0.523). If an orthogonal diameter was
missing, we substituted this value by the maximal diameter. In
centre 1, all measurements were performed by US (Acuson
X150™, Siemens Healthcare, Erlangen, Germany) by the
same investigator. In centre 2, US (Aixplorer ultrasound sys-
tem, SuperSonic Imagine, Aix-en-Provence, France; Aplio,
Toshiba Medical system, Tokyo, Japan), CT (Advantage
LightSpeed VCT, GE Healthcare, Milwaukee, United States
of America), or MRI (1.5-T imager, interna, Philips
Healthcare, Best, the Netherlands) were applied and measured
by two investigators. Both centres monitored adverse events
until six months following treatment.
Outcome variables
The primary outcome was the overall clinical response at six
months following treatment. To predict optimal clinical suc-
cess, we divided clinical outcome into two groups: complete
clinical responders that reported Bdisappearance^ or incom-
plete clinical responders that reported Breduction^, Bno
change^ or Baggravation^ of symptoms.
As a secondary outcome, technical response was evaluated
by the proportional cyst reduction at six months. From a tech-
nical point of view, we were mainly interested in patients with
a low (suboptimal) outcome to identify factors that are asso-
ciated with lower efficacy of the procedure. To do so, we
grouped technical response into patients with or without a
suboptimal response, defined by a cyst diameter reduction in
Fig. 1 Computed tomography demonstrating (asterisk) a solitary (a) and
dominant hepatic cyst in polycystic liver disease (b)
Fig. 2 Ultrasonography-guided placement of pigtail catheter to perform
aspiration (a) followed by fluoroscopy demonstrating a collapsed hepatic
cyst without leakage (b)
Fig. 3 Hepatic cyst diameter measurement by ultrasonography;
transversal (left) and coronal (right) plane to estimate hepatic cyst volume
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the lower quartile of the total sample. Secondly, we repeated
this evaluation with cyst volume reduction measurements.
Predicting variables
The following variables were selected for analysis: age at treat-
ment (years), gender, PLD (defined as>20 cysts), previous
drainage of the treated cyst, baseline cyst diameter (cm), loca-
tion of the treated cyst (right or left liver lobe), haemorrhagic
aspect of aspirated cyst fluid, volume of injected ethanol (mL),
and proportional diameter reduction (%) at one and sixmonth(s)
following aspiration sclerotherapy.
Data collection
Both centres completed an electronic form containing all var-
iables of interest. A pooled dataset was created by the initiat-
ing investigator. If possible, data inconsistencies were
corrected in agreement with both centres.
Statistical analysis
Baseline characteristics are given in mean (± SD) ormedian (±
IQR) according to distribution. Patients characterized as com-
plete clinical responder were compared with patients with an
incomplete clinical response on predefined predicting vari-
ables by univariate analysis. Similarly, we compared patients
with or without a suboptimal technical response. Variables
were selected as fixed effects in logistic regression analysis
(generalized linear mixed models) if a p-value < 0.2 was
found. To identify predictors of clinical and technical re-
sponse, we used backward selection by excluding variables
with a p-value>0.05 in the multivariate analysis. The variable
centre retained in univariate and multivariate analysis as a
random effect to correct for possible differences between cen-
tres. Within groups of symptomatic relief, we compared pro-
portional cyst diameter at six months by the non-parametric
Kruskal-Wallis test. In addition, we explored whether a sub-
optimal technical response was associated with clinical re-
sponse using the Pearson’s chi-square test. Finally, to confirm
our findings, we repeated all uni- and multivariate analyses
using cyst volume measurements instead of diameter mea-
surements. Statistical analyses were performed using IBM
SPSS software, version 20.0. P-values were two-tailed and a
value<0.05 was considered statistically significant.
Results
Baseline characteristics
A total of 93 patients was retrieved from both centres. Seven
patients were excluded from analysis (Fig. 4). Reasons for
exclusion were loss to follow-up (n=4) or inability to identify
the treated cyst from other surrounding cysts following aspi-
ration sclerotherapy (n=3). This resulted in a pooled sample
of 86 patients with a mean age at treatment of 57.8 (range 28 -
80) years (Table 2). Female patients (n=77, 89.5 %) had a
mean age of 57.0 (range 28 - 80) years, male patients (n=9)
had a mean age of 65.0 (57 – 79) years.
Cysts were most frequently localized in the right hepatic
lobe (69.8 %). PLD was present in 38.4 %. The median max-
imal diameter at baseline of the treated hepatic cyst was
11.0 cm (9.3-15.0 cm) corresponding with a median estimated
baseline volume of 696 mL (381-1584 mL). Aspect of cyst
aspirate was assessed in 84 cases: 52 (61.9 %) aspirates were
classified as clear and 32 (38.1 %) aspirates contained
haemorrhagic constituents. This was confirmed bymicroscop-
ic evaluation.
Overall clinical and technical response
At six months, 47 patients (54.7 %) reported disappearance of
symptoms and were defined as complete clinical responders.
Fig. 4 Overview of included patients
Table 2 Demographics (n= 86)
Age at treatment, mean (SD) 57.8 (10.2)
Female gender, n (%) 77 (89.5 %)
PLD, n (%) 33 (38.4 %)
Previous drainage treated cyst, n (%) 19 (22.1 %)
Location cyst in right liver lobe, n (%) 60 (69.8 %)
Cyst diameter baseline, median (IQR) 11.0 (9.3-15.0)
Cyst volume baseline, median (IRQ) 696 (381-1584)
Volume aspirate, median (IQR) 500 (300-1200)
Haemorrhagic aspect of cyst fluid, n (%) 32 (38.1 %)1
Volume of ethanol, median (IRQ) 70 (50-110)
1 Cyst fluid aspect was not characterized in two patients. Age is presented
in years, diameters in centimeters, and volumes in milliliters.
Abbreviations: PLD, polycystic liver disease; SD, standard deviation;
IQR, interquartile range
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Thirty patients (34.9 %) reported reduction, and nine patients
(10.4 %) had no change of symptoms following aspiration
sclerotherapy and were collectively defined as incomplete
clinical responders. In total, 89.6 % of patients had either
disappearance or reduction of symptoms. No patients reported
aggravation of symptoms.
Median cyst diameter decreased from 11.0 cm (9.3-
15.0 cm) to 8.6 cm (6.0-11.0 cm) one month following
aspiration sclerotherapy, corresponding to a median pro-
portional reduction of 29.7 % (17.4-39.2 %). Cyst diam-
eter regression continued to a median cyst diameter of
3.5 cm (1.0-6.4 cm) six months following aspiration
sclerotherapy, corresponding to a proportional reduction
of 70.7 % (50.0-87.2 %). In line, median proportional cyst
volume regressed by 68.0 % (40.4-78.4 %) to 264 mL
(103-605 mL) in the first month. At six months, median
volume regressed to 22 mL (1-101 mL) corresponding
with a proportional reduction of 97.8 % (87.5-99.8 %).
Overall, centre 2 reported a higher cyst reduction at six
months than centre 1: 99 % (94-100) vs 92 % (68-98 %),
respectively.
Predictors of complete clinical response
After univariate analysis, we selected location of the treated
cyst, volume of injected ethanol, proportional diameter reduc-
tion at one month, and proportional diameter reduction at six
months for subsequent regression analysis (Table 3).
Multivariate analysis identified that an increased proportional
diameter reduction at six months was associated with a com-
plete clinical response (OR 1.02, 95 % CI 1.00-1.04,
p=0.046). When we replaced proportional diameter reduction
at six months for volume measurements, statistical signifi-
cance was lost (OR 1.02, 95 % CI 0.99-1.05, p= 0.665,
Supplementary Table 1). We observed no significant centre
effect (p=0.13).
Further explorative analysis revealed that proportional di-
ameter reduction at six months was 78.6 % (60.0-92.9 %) in
patients with symptom disappearance, 62.9 % (43.4-82.8 %)
in patients with symptom reduction, and 50 % (24.5-66.4 %)
in patients who reported no change of symptoms (p-val-
ue=0.01, Fig. 5). In accordance with our diametric analysis,
patients with symptom disappearance showed a statistically
significant higher median volume reduction at six months of
99.0 % (94.1-100 %), compared to 94.4 % (79.1-99.5 %) and
87.5 % (60.6-95.9 %) in patients with reduction or no change
of symptoms, respectively (p-value=0.02).
Predictors of suboptimal technical response
The lower quartile in technical response (n=22) was defined
by a proportional diameter reduction of<50.0% and a volume
reduction of<87.5 %, characterized as suboptimal technical
response.
Baseline cyst diameter, proportional cyst diameter reduc-
tion after one month, and aspect of cyst fluid were selected for
subsequent regression analysis (Table 4). By multivariate
analysis, we identified that patients with lower diameter re-
duction at one month had higher risk of having a suboptimal
technical response at six months (OR 1.06, 95%CI 1.02-1.10,
p<0.01). In addition, cysts containing haemorrhagic fluid
were associated with a suboptimal technical response (OR
4.39, 95 % CI 1.34-14.39, p=0.02). We confirmed our find-
ings when diameter outcome and predictors were replaced by
volume measurements (Supplementary Table 2). A subopti-
mal technical response was predicted by a lower volume re-
duction at one month (OR 1.04, 95 % CI 1.02-1.06, p<0.01)
and haemorrhagic cyst fluid (OR 4.78, 95 % CI 1.38-16.54,
Table 3 Predictors of complete clinical response, univariate and multivariate analysis
Independent variable Complete
response (n = 47)
Incomplete
response (n= 39)
Univariate
analysis, p-value
Multivariate analysis,
Odds ratio (95 % CI)
Multivariate
analysis, p-value
Age at treatment, mean (SD) 57.9 (10.3) 57.7 (10.3) 0.962
Female gender, n (%) 44 (93.6) 33 (84.6) 0.227
PLD, n (%) 16 (34.0) 17 (43.6) 0.402
Previous drainage of treated cyst, n (%) 9 (23.1) 10 (21.3) 0.889
Baseline cyst diameter, mean (SD) 11.8 (3.5) 12.7 (4.0) 0.260
Location cyst in right liver lobe, n (%) 30 (63.8) 30 (76.9) 0.179 1.74 (0.62-4.86) 0.288
Haemorrhagic aspect of cyst fluid, n (%)1 17 (63.0) 15 (60.5) 0.940
Volume of ethanol, median (IQR) 80.0 (40.0-110.0) 50.0 (50.0-110.0) 0.143 0.99 (0.97-1.01) 0.319
Proportional diameter reduction one
month, median (IQR)
32.1 (21.4-45.5) 27.6 (11.8-36.7) 0.118 1.01 (0.98-1.04) 0.425
Proportional diameter reduction six
months, median (IQR)
78.6 (60.0-92.3) 59.1 (39.2-81.3) 0.046 1.02 (1.00-1.04) 0.046
1 Cyst fluid aspect was not characterized in two patients. Age is presented in years, diameter in centimeters, volume in milliliters and proportional
reductions in percentages. Abbreviations: PLD, polycystic liver disease; SD, standard deviation; IQR, interquartile range
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p = 0.01). Again, we found no significant centre effect
(p=0.06). Finally, explorative analysis revealed that 8 of 22
(36.4 %) patients with a suboptimal technical response had
complete clinical response, compared to 39 of 64 (60.9 %)
patients without a suboptimal technical response, a difference
that was statistically significant (p=0.046).
Safety
Overall, nine adverse events (10.7 %) occurred. Four patients
developed an adverse event immediately after treatment, these
included: hypotension (n=2), transient fever (n=1), and a
cyst haemorrhage (n=1). During follow-up, four patients re-
ported pain between 2-24 days after treatment, in three of
these patients a cyst haemorrhage was suspected based on
clinical and radiological presentation. Finally, one patient de-
veloped an hepatic cyst infection (n=1), which was treated
adequately by antibiotic treatment. The remaining adverse
events were managed by conservative treatment. All adverse
events resolved without sequelae.
Discussion
The primary finding of this study is that a strong hepatic cyst
reduction following aspiration sclerotherapy predicts com-
plete clinical response. We also identified that haemorrhagic
cyst aspirate and a limited cyst size reduction at one month
predicted suboptimal long-term cyst reduction but did not af-
fect clinical response.
Clinical efficacy in this pooled cohort was high as 89.6 %
of treated patients reported reduction of symptoms while
symptoms disappeared completely in 54.7 %. The literature
contains four large studies that assessed symptomatic response
following aspiration sclerotherapy with various sclerosing
agents. Similar to our results, these studies reported reduction
of symptoms in 72.0-92.2 %, while 46.1-85.0 % had complete
resolution of symptoms [7, 10, 18, 19]. However, these studies
failed to investigate which factors contribute to clinical treat-
ment response. We used the model of an individual patient
data analysis with data coming from two independent cohorts,
to demonstrate that a significant reduction of the treated cyst
was associated to a better overall clinical response. Indeed,
patients with a cyst diameter reduction over 50 % were more
likely to have complete clinical response. This underlines that
effective technical success is needed to increase the patients’
chance to benefit of treatment.
We observed a median proportional diameter reduc-
tion of 71 % at six months following aspiration sclero-
therapy, corresponding with a volume reduction of
98 %. This strong reduction rate is comparable to other
studies that evaluated long-term technical success of aspira-
tion sclerotherapy. These studies achieved a proportional di-
ameter reduction ranging from 54.8-85.7 % after 12-48
months [7, 20–22]. Correspondingly, studies that reported ef-
ficacy in terms of proportional volume reduction ranged from
90.8-98.9 % following 12-30 months [18, 23–25].
Fig. 5 Proportional cyst diameter reduction within groups of symptom
relief at six months
Table 4 Predictors of suboptimal technical response, univariate and multivariate analysis
Independent variable Suboptimal
response (n = 22)
No suboptimal
response (n= 64)
Univariate
analysis, p-value
Multivariate analysis,
odds ratio (95 % CI)
Multivariate
analysis, p-value
Age at treatment, mean (SD) 60.6 (9.8) 56.8 (10.2) 0.095 1.04 (0.98-1.10) 0.202
Female gender, n (%) 19 (86.4) 58 (90.6) 0.712
PLD, n (%) 9 (40.9) 24 (34.5) 0.860
Previous drainage of treated cyst, n (%) 4 (18.2) 15 (23.4) 0.536
Baseline cyst diameter, mean (SD) 13.6 (4.4) 11.7 (3.4) 0.046 1.10 (0.94-1.29) 0.239
Location cyst in right liver lobe, n (%) 16 (72.7) 44 (68.8) 0.692
Haemorrhagic aspect of cyst fluid, n (%)1 13 (59.1) 19 (29.7) 0.034 4.39 (1.34-14.39) 0.015
Volume of ethanol, median (IQR) 50.0 (47.5-110.0) 50.0 (50.0-110.0) 0.320
Proportional diameter reduction one
month, median (IQR)
17.1 (4.1-36.7) 32.0 (24.6-45.2) 0.009 1.06 (1.02-1.10) 0.007
1 Cyst fluid aspect was not characterized in two patients. Age is presented in years, diameter in centimeters, volume in milliliters and proportional
reductions in percentages. Abbreviations: PLD, polycystic liver disease; SD, standard deviation; IQR, interquartile range
746 Eur Radiol (2017) 27:741–748
Sclerotherapy of hepatic cysts containing haemorrhagic fluid
is not contraindicated and leads to reduction of the cyst [13].
Nonetheless, we found that drainage of haemorrhagic cyst fluid
predicted an increased risk of a suboptimal technical treatment
response. This may be the result of several factors. Due to
increased viscosity, residues of haemorrhagic cyst fluid may
remain in the cyst following drainage, leading to a diluted con-
centration of the sclerosing agent [7, 26]. Alternatively, clots or
debris in the cyst may prevent contact with the cyst wall [10]. A
spontaneous cyst bleeding is estimated to occur in around 8 %
of hepatic cysts [27]. Remarkably, 32 (38 %) patients in our
sample had cyst fluid containing haemorrhagic constituents.
This relatively large proportion of haemorrhagic cyst fluid in
treated patients may result of the symptomatic course following
a cyst bleed, ultimately leading to treatment of the cyst. In this
study, haemorrhagic content was not associated to a reduced
clinical response. The present results validate the use of aspira-
tion sclerotherapy in this subgroup of patients.
Furthermore, we found that a lower cyst reduction at one
month predicted a suboptimal technical response at six months.
Intracystic fluid re-accumulation directly following aspiration
sclerotherapy is a well-known phenomenon that leads to a re-
stricted cyst reduction in the first week(s) [28]. Although tem-
porary, the cyst may relapse completely following aspiration
sclerotherapy [24]. Previous studies speculated that secretory
function of cyst-lining epithelial cells may persist following
sclerotherapy; others considered fluid re-accumulation as a
component of inflammatory response [7, 29]. Although tran-
sient in most cases, we found that a strong relapse predicted a
suboptimal long-term cyst reduction.
Apart from aspiration sclerotherapy, surgical fenestration is
often advocated as a primary treatment option for hepatic
cysts. In a review of 43 studies (311 patients) evaluating effi-
cacy and safety of cyst fenestration, reduction of symptoms
was found in 92 % of treated patients [8]. This clinical re-
sponse is consistent with our results. However, 22 % of lapa-
roscopic procedures were converted to open fenestration and
overall morbidity following cyst fenestration was reported in
23 % of cases, whereas in our study 11 % of patients experi-
enced an adverse event. Our results suggest that aspiration
sclerotherapy has comparable clinical efficacy with lower
morbidity rates compared to its surgical alternative.
In this study, we confirm that aspiration sclerotherapy is
highly effective in reducing symptoms. Therefore, we advo-
cate that aspiration sclerotherapy should be primary treatment
for patients with a symptomatic, solitary, or dominant hepatic
cyst. In patients with haemorrhagic cyst fluid aspirate or a
strong fluid reaccumulation following aspiration sclerothera-
py, we advise increased attention. If symptoms recur, initiation
of a subsequent aspiration sclerotherapy or referral for surgical
treatment may be favourable.
The main strength of this study is that we pooled results of
two similar studies from different countries and thereby
increased the generalizability of our results. Moreover, this
relatively large sample size enabled us to evaluate predictors
of treatment response. Some limitations come with this study.
Firstly, symptomatic change was evaluated by two different
questionnaires. A detailed evaluation of specific symptoms
could not be performed due to differences between these in-
struments. However, as both instruments assessed overall
symptomatic response in a comparable standardized manner,
we were able to pool results of overall clinical response and
believe that possible introduced bias is limited. Secondly, due
to small numbers of patients without reduction of symptoms,
we grouped patients with Breduction^ of symptoms and Bno
change^ as incomplete clinical responder. As a result, we
were unable to evaluate predicting variables of clinical non-
responders. Furthermore, our follow-up extends over a period
of six months and should ideally be validated over a longer
period. However, we regard six months as sufficient as the
most prominent cyst regression occurs within these first
months and sustains thereafter [24]. Moreover, cyst diameter
measurements were performed by different imaging modali-
ties and investigators between centres; this could have led to
differences in outcome measurements. Finally, duration of
ethanol instillation differed between centre 1 and centre 2.
As this was completely co-linear to centre, we could not in-
clude this variable in our analysis. A prolonged exposure of
the sclerosing agent to the cyst wall may improve efficacy of
treatment. On the other hand, previous studies stated that eth-
anol eliminates epithelial cells within minutes [24, 30]. The
impact of duration of sclerotherapy on treatment efficacy re-
mains to be tested.
To conclude, aspiration sclerotherapy of hepatic cysts ef-
fectively reduces symptoms in the vast majority of patients.
Chance of complete clinical response is increased in patients
with higher proportional cyst reduction. We identified that a
limited cyst reduction in the first month and the presence of
haemorrhagic cyst fluid predict a suboptimal technical treat-
ment response, however, these variables did not predict symp-
tom disappearance.
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